Eli Lilly and Company (NYSE:LLY) Shares Acquired by Certified Advisory Corp

Certified Advisory Corp boosted its position in Eli Lilly and Company (NYSE:LLY) by 0.8% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 4,095 shares of the company’s stock after acquiring an additional 31 shares during the period. Certified Advisory Corp’s holdings in Eli Lilly and Company were worth $3,628,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Bellevue Group AG increased its position in Eli Lilly and Company by 3.1% during the first quarter. Bellevue Group AG now owns 57,965 shares of the company’s stock worth $45,094,000 after purchasing an additional 1,753 shares during the last quarter. Ceeto Capital Group LLC grew its stake in shares of Eli Lilly and Company by 4.9% during the 1st quarter. Ceeto Capital Group LLC now owns 2,130 shares of the company’s stock valued at $1,657,000 after buying an additional 100 shares during the period. Morse Asset Management Inc increased its holdings in shares of Eli Lilly and Company by 6.7% during the 1st quarter. Morse Asset Management Inc now owns 11,139 shares of the company’s stock worth $8,666,000 after buying an additional 701 shares during the last quarter. Beaird Harris Wealth Management LLC boosted its holdings in Eli Lilly and Company by 10.6% in the first quarter. Beaird Harris Wealth Management LLC now owns 501 shares of the company’s stock valued at $390,000 after acquiring an additional 48 shares during the last quarter. Finally, Mount Yale Investment Advisors LLC grew its position in Eli Lilly and Company by 6.7% during the first quarter. Mount Yale Investment Advisors LLC now owns 4,408 shares of the company’s stock valued at $3,429,000 after acquiring an additional 278 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,480 shares in the company, valued at $4,402,522.40. The trade was a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.13% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on LLY. Cantor Fitzgerald restated an “overweight” rating and issued a $885.00 price objective on shares of Eli Lilly and Company in a report on Monday, September 16th. Bank of America reduced their price target on shares of Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating on the stock in a research report on Thursday, October 31st. Barclays dropped their price objective on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research report on Thursday, October 31st. Redburn Atlantic upgraded shares of Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. Finally, Citigroup increased their price target on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the company a “buy” rating in a report on Friday, October 25th. Four analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $1,007.94.

Eli Lilly and Company Price Performance

LLY opened at $748.01 on Friday. The company has a market capitalization of $710.10 billion, a P/E ratio of 80.87, a PEG ratio of 2.84 and a beta of 0.43. The company has a 50-day moving average of $865.01 and a 200-day moving average of $869.01. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. Eli Lilly and Company has a 1-year low of $561.65 and a 1-year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The firm had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. During the same period in the prior year, the firm earned $0.10 earnings per share. The firm’s quarterly revenue was up 20.4% compared to the same quarter last year. Equities analysts expect that Eli Lilly and Company will post 13.2 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 0.70%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio is presently 56.22%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.